Sermonix Pharmaceuticals
Manufacturing · Ohio, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3000 E Main St Unit 218, Columbus, Ohio,...Phone Number
(614) 864-4919Website
www.sermonixpharma.comRevenue
$8.4 MillionIndustry
About Sermonix Pharmaceuticals
Sermonix Pharmaceuticals Org Chart
Is Sermonix Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Sermonix Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Sermonix Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Sermonix Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Sermonix Pharmaceuticals launches new products
Earning: See what the market has to say on Sermonix Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Sermonix Pharmaceuticals
Click to see if Sermonix Pharmaceuticals had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Sermonix Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Sermonix Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Sermonix Pharmaceuticals
Compare insights from companies similar to Sermonix Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Sermonix Pharmaceuticals
Company Profile Activity
Activity Insights
Sermonix Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sermonix Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sermonix Pharmaceuticals.
Sermonix Pharmaceuticals financials insights
Gather financial insights about Sermonix Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Debt
$1M
Private Equity
$2M
Angel/Seed
$4.2M
Series A
$66M
Sermonix Pharmaceuticals Tech Stack
A closer look at the technologies used by Sermonix Pharmaceuticals
Most Recent Scoops
Sermonix Pharmaceuticals News & Media
Sermonix and Henlius Dose First Chinese Patient in Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
COLUMBUS, Ohio, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), today announced that its partner in Asia, Shanghai Henlius Biotech, Inc. (2696.HK), dosed its first Chinese patient in the Phase 3 global registrational ELAINE-3 trial.Sermonix Surveys Find Vaginal/Sexual Health Symptoms Are Among Most Significant Issues Affecting Lives of ER+/HER2- Metastatic Breast Cancer Patients
The results, shared in an oral presentation at RISE UP for Breast Cancer, demonstrate the great need for well-tolerated breast cancer therapies that do not diminish important aspects of patient quality of life The results, shared in an oral presentation at RISE UP for Breast Cancer, demonstrate the great need for well-tolerated breast cancer therapies that do not diminish important aspects of patient quality of lifeSermonix Pharmaceuticals’ Lasofoxifene Is Well Tolerated, Demonstrates Promising Ki67 Suppression in Phase 2 I-SPY 2 Arm Evaluating Therapy in Neoadjuvant Breast Cancer Setting
COLUMBUS, Ohio, and SAN FRANCISCO, Nov. 02, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), and Quantum Leap Healthcare Collaborative™ today broadly announced that in the Phase 2 clinical trial evaluating lasofoxifene as a neoadjuvant endocrine therapy in molecularly selected HR+/HER2-, locally advanced breast cancer, the investigational drug was well tolerSermonix Pharmaceuticals to Host Oral Presentation on Vaginal and Sexual Health at RISE UP for Breast Cancer Conference
Sermonix will also present a poster on the results of its Phase 2 trial evaluating neoadjuvant lasofoxifene in molecularly selected HR+/HER2-, locally advanced breast cancer Sermonix will also present a poster on the results of its Phase 2 trial evaluating neoadjuvant lasofoxifene in molecularly selected HR+/HER2-, locally advanced breast cancer
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Sermonix Pharmaceuticals
Founded in 2014 and headquartered in Colombus, United States, Sermonix Pharmaceuticals is a biopharmaceutical company with a precision medicine focus for bringing targeted oncology products through development, approval, and commercialization.... Read More